Extended release formulations of erythromycin derivatives
US6551616B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 13, 1999 |
| Grant date | Apr 22, 2003 |
| Priority date | — |
| Expiry date | Dec 17, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2018
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.